Ulcerative Colitis (UC) is characterized by chronic inflammation of the mucosal layers of the colon. Treatment of refractory UC is challenging and has a huge healthcare burden. Although there have been advancements in immunomodulatory therapies, these require a step-up financially, and these medications are also associated with significant adverse events. Curcumin, an active ingredient of turmeric, has been studied in the past and found to be useful in the treatment of UC when used as an adjuvant along with mesalamine. We did a systematic review and meta-analysis to explore the role curcumin plays in clinical and endoscopic remission in patients with UC.
Materials and Methods
A comprehensive literature review was conducted by first searching the MEDLINE, Pubmed, and Embase databases through December 2017 to identify all studies that compared the use of curcumin when used along with mesalamine with placebo for clinical and endoscopic improvement and remission.
Three randomized controlled trials including 142 patients were included in the study. Use of curcumin along with mesalamine was associated with increased odds of clinical remission (pooled odds ratio of 6.78, 95% CI: 2.39-19.23, P = 0.042). Clinical improvement, endoscopic remission and improvement rate also trended higher in the curcumin group compared to placebo.
This study demonstrates higher clinical remission rates when curcumin was used in combination with mesalamine to achieve remission in patients with UC. Curcumin, due to its cost effectiveness and safer side effect profile, can decrease the healthcare burden and morbidity associated with this relapsing and remitting disease.
Key Indexing Terms
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of the Medical Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.Can J Gastroenterol. 2005; 19 (Suppl A): 5A-36A
- Extracolonic diagnoses in ulcerative colitis: an epidemiological study.Am J Gastroenterol. 1990; 85: 711-716
- Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.Gastroenterology. 2008; 135: 1907-1913
- Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium.J Gastroenterol Hepatol. 2007; 22: 1846-1851
- Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.Gastroenterology. 2014; 146 (e3): 392-400
- Curcumin for maintenance of remission in ulcerative colitis.Cochrane Database Syst Rev. 2012; 10:CD008424
- Curcumin attenuates diet-induced hypercholesterolemia in rats.Med Sci Monit. 2005; 11: BR228-BR234
- Mechanism of the anti-inflammatory effect of curcumin: PPAR-gamma activation.PPAR Res. 2007; 2007: 89369
- Possible neuroprotective mechanisms of curcumin in attenuating 3-nitropropionic acid-induced neurotoxicity.Methods Find Exp Clin Pharmacol. 2007; 29: 19-25
- Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease.J Clin Psychopharmacol. 2008; 28: 110-113
- Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells.Int J Oncol. 2008; 32: 1119-1123
- Prophylactic role of curcumin in dextran sulfate sodium (DSS)-induced ulcerative colitis murine model.Food Chem Toxicol. 2009; 47: 1311-1317
- Curcumin preventsand ameliorates trinitrobenzene sulfonic acid-induced colitis in mice.Gastroenterology. 2002; 123: 1912-1922
- Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial.Clin Gastroenterol Hepatol. 2015; 13 (e1): 1444-1449
- Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis – a randomized, placebo-controlled, pilot study.J Crohns Colitis. 2014; 8: 208-214
Banerjee R, Penmetsa A, Medaboina K, et al. Novel bio-enhanced curcumin with mesalamine for induction of remission in mild to moderate ulcerative colitis. Gastroenterology 2017;152(5):S587.
- Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.Clin Gastroenterol Hepatol. 2006; 4: 1502-1506
- Curcumin therapy in inflammatory bowel disease: a pilot study.Dig Dis Sci. 2005; 50: 2191-2193
- Measuring inconsistency in meta-analyses.BMJ. 2003; 327: 557-560
- Curcumin anti-apoptotic action ina model of intestinal epithelial inflammatory damage.Nutrients. 2017; 9: 578https://doi.org/10.3390/nu9060578
- Molecular mechanisms of curcumins suppressing effects on tumorigenesis, angiogenesis and metastasis, focusing on NF-κB pathway.Cytokine Growth Factor Rev. 2016; 28: 21-29
- Update on the etiology, pathogenesis and diagnosis of ulcerative colitis.Nat Clin Pract Gastroenterol Hepatol. 2004; 1: 26-31
- Ulcerative colitis and colorectal cancer. A population-based study.N Engl J Med. 1990; 323: 1228-1233
Published online: July 02, 2018
Accepted: June 25, 2018
Received: February 20, 2018
☆The authors have no financial or other conflicts of interest to disclose.
✯✯Source of funding: None declared.
© 2018 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.